Analyst Ratings for Foghorn Therapeutics
Portfolio Pulse from Benzinga Insights
Foghorn Therapeutics (NASDAQ:FHTX) has received positive analyst ratings in the last quarter, with 6 bullish and 3 somewhat bullish ratings. The average 12-month price target for the company is $18.0, a 10.0% decrease from the previous average price target of $20.00.
June 28, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Foghorn Therapeutics has received positive analyst ratings, which could potentially boost investor confidence and stock price.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Foghorn Therapeutics indicate a positive outlook for the company, which could potentially lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100